| Filed On | Filing |
|---|---|
| 20 Aug 2026 |
Form 4: Tousignant Jennifer, Chief Legal Officer
Sold 14,212 shares ($348K) · Received 10,000 shares by exercise or conversion ($144K) |
| 20 Aug 2026 | SCHEDULE 13G |
| 19 Aug 2026 | 144 |
| 18 Aug 2026 |
Form 4: Tripuraneni Radhika, Chief Medical Officer
Received 40,000 shares by exercise or conversion ($528K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 07 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 02 Jul 2026 |
Form 4: Cain Christopher W., Director
Granted 32,341 Stock Option (Right to Buy) |
| 02 Jul 2026 |
Form 4: Ajer Jeffrey Robert, Director
Granted 32,341 Stock Option (Right to Buy) |
| 02 Jul 2026 |
Form 4: Moses Jennifer K., Director
Granted 32,341 Stock Option (Right to Buy) |
| 02 Jul 2026 |
Form 4: Gheuens Sarah, Director
Granted 32,341 Stock Option (Right to Buy) |
| 02 Jul 2026 |
Form 4: Kiselak Tomas, Director
Granted 32,341 Stock Option (Right to Buy) |
| 02 Jul 2026 |
Form 4: Morris Arlene, Director
Granted 32,341 Stock Option (Right to Buy) |
| 29 Jun 2026 | 8-K: Regulation FD Disclosure; Other Events |
| 26 Jun 2026 | SCHEDULE 13G |
| 03 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
Loading...
